2023-04-20 09:59:56
ABL Bio (CEO Lee Sang-hoon) announced on the 20th that it announced the results of preclinical studies of ‘ABL102 (development code name)’, an immuno-oncology drug pipeline (new drug candidate), in the form of a poster at the American Association for Cancer Research (AACR 2023).
ABL102, a bispecific antibody that targets both ROR1 and 4-1BB, is designed to activate the clustering of 4-1BB depending on the expression of ROR1. Since ROR1 is selectively expressed only in the microtumor environment where target cancer cells exist, it prevents 4-1BB from being activated in normal cells. For this reason, it is possible to maintain the ‘Memory T Cell’ function, a unique function of 4-1BB, which prevents recurrence by remembering previously invaded antigens while minimizing the side effects of 4-1BB, which is toxic when used as a single antibody. done.
In this preclinical poster, these strengths of ABL102 were introduced in detail along with excellent data. According to the announcement, ABL102 showed excellent tumor suppression effect through complete remission (CR) in a mouse model. In an experiment in which the previously exposed tumor was reintroduced to the mouse three months later, the activation of the memory T cell function of 4-1BB was demonstrated while the tumor was suppressed for a long time.
In addition, in the primate model, as a result of a comprehensive safety evaluation including death, body weight, blood, liver toxicity, clinical chemical reaction and pathology of the experimental model, excellent safety was confirmed even at high doses of up to 100 mg/kg.
Lee Sang-hoon, CEO of ABL Bio, said, “ROR1 is expressed in various types of cancer, from solid cancer to hematological cancer, and is an antibody that global big pharmas are paying attention to.” I might feel the market’s high interest in it.”
1681993302
#ABL #Bio #presented #poster #preclinical #immunooncology #drug #AACR
